# Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment

> **NCT04558918** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 97 (actual)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria (PNH)

## Interventions

- **DRUG:** LNP023
- **DRUG:** Eculizumab
- **DRUG:** Ravulizumab

## Key facts

- **NCT ID:** NCT04558918
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-25
- **Primary completion:** 2022-09-26
- **Final completion:** 2023-03-06
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04558918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04558918, "Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04558918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*